
|Articles|April 1, 2001
- Pharmaceutical Executive-04-01-2001
- Volume 0
- Issue 0
Liberated?
Author(s)Wayne Koberstein
Patents before profits. That soundbite snagged my ears and turned my full attention to the CNN business report. I recognized the voice and the face}Ray Gilmartin, chairman of Merck. Calmly and reasonably, he explained how extraordinary circumstances in the developing world demand that his company uncouple the normally fused objectives of high profitability and unwavering patent protection.
Advertisement
Articles in this issue
about 25 years ago
Internet DTC - Minding Your P's & Q'sabout 25 years ago
Regulation: Two-Track Planabout 25 years ago
Policy: Tectonic Shiftabout 25 years ago
A Matter of Tasteabout 25 years ago
Partnerships: Bargaining Biotechsabout 25 years ago
Pediatric Mandateabout 25 years ago
Genentech's Passion for Patientsabout 25 years ago
Regulation: OK After AllNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Medical Supply Chains at Risk Over Escalating Conflicts in Iran: Report
2
Novavax Stock Increases as Shah Capital Plans to Vote Against Board Nominees
3
Q&A: Supply Chain Fallout From Iran War, Tariff Uncertainty
4
What Unexpected Costs do GLP-1 Patients Face?
5




